tbuckley/cabot-search huggingface dataset:
Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma, Receiving Bisphosphonate Therapy, Is Independent of Renal Function: Single Institute Experience of an Emerging Clinical Problem.
Authors: Rami Manochakian, Jean-Gabriel Coignet, Swaminathan Padmanabhan, Maureen Sullivan, Kena C. Miller, Asher Alban Chanan-Khan
Journal: Blood (2006)
AB0627 Predictors of Ild and Its Progression in A Cohort of Scleroderma Patients from Western India: A Prospective Observational Cohort Study: Table 1.
Authors: Y. Gc, R. Samant, A. Mahashur, P.S. Sagdeo, G. Kakade
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pulmonary involvement, including both interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), has become the primary cause of Scleroderma-related death. Little data has been published from India regarding the progression of ILD and Pulmonary arterial hypertension in Scleroderma. <h3>Objectives</h3> 1) To identify baseline factors predictive of ILD and its outcome in patients with Scleroderma. 2) To study the progression of ILD and PAH in scleroderma patients 3) To study the demographic and clinical profile of scleroderma patients from Western India. <h3>Methods</h3> Prospective observational study involving 68 patients. Patients were evaluated at 0,3,6,9 and 12 months. Patient9s demographic and clinical details were recorded at baseline. Other than routine tests, Anti-nuclear antibodies (ANA), Spirometry, diffusing capacity of lung for carbon monoxide (DLCO) measurement, high resolution computed tomography (HRCT) of thorax, 6-minute walk test and echocardiography were done. <h3>Results</h3> Study included 68 individuals with Scleroderma (according to the American College of Rheumatology classification criteria for SSc) with majority of cases being females n=64 (94.1%). ILD was seen in 53 (77.9%) patients with a mean duration of 4.17 years. When we compared the mean change in FVC, DLCO and PAH from the time of onset of ILD/PAH to the values at last follow up, there was no significant change. ILD patients with UIP pattern on HRCT, showed a significant progression in terms of &gt;10% fall in FVC as compared to NSIP subgroup. None of the baseline parameters were predictive of ILD and its progression. Older age predicted onset of PAH. <h3>Conclusions</h3> 1) None of the studied baseline variables were predictive of ILD and its progression. 2) Only age had statistically significant effect as a predictor for the occurrence of PAH. 3) The demographic and clinical profile of our cohort was comparable to other studies from India and western population. Calcinosis and telangiectasia were less frequently seen as compared with western population. <h3>References</h3> Kumar U, Ramteke R, Yadav R, Ramam M, Handa R, Kumar A. Prevalence and predictors of pulmonary artery hypertension in systemic sclerosis. J Assoc Physicians India. 2008 Jun;56:413–7. <h3>Disclosure of Interest</h3> None declared
P1045 : Ultra-high-field MR-spectroscopy in NAFLD as non-invasive in-vivo tool for monitoring changes in fat and energy metabolism with potential identification of NASH and advanced fibrosis by saturation transfer technique
Authors: S. Traussnigg, C. Kienbacher, M. Gajdošík, L. Valkovič, H. Hofer, P. Ferenci, F. Wrba, S. Trattnig, M. Krššák, M. Trauner
Journal: Journal of Hepatology (2015)
“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”.
Authors: Karolin Behringer, Horst Mueller, Hans-Henning Flechtner, Corinne Brillant, Teresa Halbsguth, Thomas Schober, Hiltrud Nisters-Backes, Andreas Engert, Peter Borchmann
Journal: Blood (2009)
Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty
Authors: David R. Anderson, Michael J. Dunbar, Eric R. Bohm, Etienne Belzile, Susan R. Kahn, David Zukor, William Fisher, Wade Gofton, Peter Gross, Stephane Pelet, Mark Crowther, Steven MacDonald, Paul Kim, Susan Pleasance, Nicki Davis, Pantelis Andreou, Philip Wells, Michael Kovacs, Marc A. Rodger, Tim Ramsay, Marc Carrier, Pascal-Andre Vendittoli
Journal: Annals of Internal Medicine (2013)

Results: Five of 398 patients (1.3%) randomly assigned to dalteparin and 1 of 380 (0.3%) randomly assigned to aspirin had VTE (absolute difference, 1.0 percentage point [95% CI, 0.5 to 2.5 percentage points]). Aspirin was noninferior (P 0.001) but not superior (P 0.22) to dalteparin. Clinically significant bleeding occurred in 5 patients (1.3%) receiving dalteparin and 2 (0.5%) receiving aspirin. The absolute between-group difference in a composite of all VTE and clinically significant bleeding events was 1.7 percentage points (CI, 0.3 to 3.8 percentage points; P 0.091) in favor of aspirin. Limitation: The study was halted prematurely because of difficulty with patient recruitment. Conclusion: Extended prophylaxis for 28 days with aspirin was noninferior to and as safe as dalteparin for the prevention of VTE after THA in patients who initially received dalteparin for 10 days. Given its low cost and greater convenience, aspirin may be considered a reasonable alternative for extended thromboprophylaxis after THA.
Imatinib Mesylate Induces High Complete Cytogenetic and Molecular Response Rates in Children and Adolescents with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP)
Authors: Fiorina Giona, Maria Caterina Putti, Maria Luisa Moleti, Mauro Nanni, Anna Maria Testi, Stefania Varotto, Enrico Marco Gottardi, Annalisa De Vellis, Vittorio Nunes, Daniela Diverio, Anna Leszl, Giuseppe Saglio, Robert Foà
Journal: Blood (2008)
AB0037 Characterising Multiple Molecule-Modulating Response of TNF-Alpha and Interleukin-6 by Combination of Methotrexate and Aconite in Interferon Gamma-Induced Toxicity Setting
Authors: D.-S. Oh, G. Park, S. Choi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> TNF-alpha (TNF-α) and interleukin-6 (IL-6) are one of the molecules which have been the targets of interest in rheumatoid arthritis (RA). Among the therapeutic strategies, simultaneous modulation of the two is regarded as providing the stability on the networks of the relevant molecules and sufficient profile for multi-therapeutic targets. <h3>Objectives</h3> To characterise multiple molecule-modulating profile of TNF-α and IL-6, we experimented the anti-inflammatory phenotypes of the two by adopting well-known therapeutic, methotrexate (MTX) and newly recognised herbal, aconite (<i>Aconitum carmichaelii</i>) in the setting of interferon-gamma-induced inflammatory toxicity in macrophage. <h3>Methods</h3> Mouse macrophage Raw264.7 cells were treated with MTX (0.01–1 mM) and processed aconite (Aconibal®, 0.01–1 mg/mL). The levels of TNF-α and IL-6 were measured by spectrophotometre (VersaMax ELISA, Molecular devices, USA), then, as a parametric approach, median and dose effect were analysed to calculate the combination index (CI) and standard isobologramme were presented using CalcuSyn software (CalcuSyn 2.0, Biosoft, UK). <h3>Results</h3> Anti-inflammatory phenotypes of TNF-α and IL-6 level were shown in aconite dose-dependent manner. The doses of 0.75 mg/mL of aconite and 0.25 mM of MTX indicated the lowest CI as 0.272 for TNF-α and 7916 for IL-6, which was sparing effect compared with single treat by 3.9 mM and 0.6 mM of MTX, respectively. Reflecting the response, TNF-α was modulated with the synergistic profiles in normalised isobologramme. <h3>Conclusions</h3> Stable modulation of TNF-α and IL-6 and synergistic response on TNF-α were characterised. Further approaches on network stability of the relevant molecules are needed. <h3>References</h3> Zhao W, Yang H. Statistical Methods in Drug Combination Studies. CRC Press 2015 ISBN 978–1-4822–1674–5. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010 Jan 15;70(2):440–6. Detert J, Klaus P. Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics 2015;9:35–43. Park G, Kim KM, Choi S, Oh DS. Aconitum carmichaelii protects against acetaminophen-induced hepatotoxicity via B-cell lymphoma-2 protein-mediated inhibition of mitochondrial dysfunction. Environ Toxicol Pharmacol in press doi:10.1016/j.etap.2016.01.012 <h3>Acknowledgement</h3> The study was funded by Korea Institute of Oriental Medicine (KIOM) which grant number was K16253. <h3>Disclosure of Interest</h3> None declared
A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies
Authors: Dalia El-Gamal, Zachary A. Hing, Shaneice Mitchell, Taylor D. LaFollette, Paul J. Brennan, Joseph M. Flynn, Jeffrey A. Jones, Farrukh Awan, Leslie A. Andritsos, James S. Blachly, Katie Williams, Bonnie K. Harrington, Virginia M. Goettl, Jennifer A. Woyach, Amy M. Lehman, Lianbo Yu, John C. Byrd, Rosa Lapalombella
Journal: Blood (2015)
Increased susceptibility of MDM2 amplified cell lines to MDM2-p53 inhibitors is associated with a high turnover of MDM2 and p53
Authors: Shafiq U. Ahmed, Claire Hutton, John Lunec
Journal: Cancer Research (2004)

3006   The MDM2 oncoprotein and the p53 tumour suppressor form an autoregulatory loop in normal cells. The  MDM 2 gene is a target for direct transcriptional activation by p53, while the MDM2 protein binds and negatively regulates the transcriptional activity of p53, as well as targeting it for proteasomal degradation. Inactivation of the p53 tumour suppressor by elevated MDM2 expression and/or activity has been implicated in a range of cancers. Inhibitors of the MDM2-p53 interaction are therefore candidates for activation of the p53 pathway in tumours expressing wild type p53. We have previously shown that a peptide analogue, AP-B, structurally based on the p53 binding domain for MDM2, was able to preferentially release the growth inhibitory and pro-apoptotic functions of p53 in wild type p53 cell lines amplified for  MDM 2 (SJSA and LS) compared to cell lines with a normal  MDM 2 gene copy number (A2780 and HCT116) (Farnie  et al . 2003. Proceedings of the AACR, Abs 657). Another study has shown similar results with the AP peptide (Chene  et al ., 2002 FEBS letters  529:  293-297) and we have seen the same trend with small molecule antagonists of MDM2-p53 binding. The aim of this study was to test the hypothesis that the sensitivity of  MDM 2 amplified cells to such antagonists is due to a higher turnover rate of p53 compared with non-amplified cells. The turnover of MDM2 and p53 in these cell lines was investigated by Western blot analysis using 100μM cycloheximide to block  de novo  protein synthesis, enabling the rate of degradation of the proteins to be measured, or 50μM of ALLN, a proteasome inhibitor, to monitor the rates of protein increase. Proteins were detected and measured by Enhanced Chemiluminescence and quantitative densitometry. The results are presented as mean values ± the standard error. The half lives of both MDM2 and p53 were smaller in the MDM2 amplified cell lines (SJSA = 31±1.7 & LS = 37±3.3 for MDM2; SJSA = 104±11 & LS = 105±9 for p53) than MDM2 non-amplified cells (A2780 = 75±5 & HCT116 = 123 ±12 for MDM2; A2780 = 164±14 & HCT116 = 230±6 for p53). Furthermore, the rate of increase of MDM2 and p53 levels when degradation was blocked by treatment with ALLN was greater in the amplified cell lines, with average doubling times of 8.5 (±1.5) vs 2.0 (±0.5) hours for p53, and 9.0 (±2.5) vs 3.0 (±1.0) hours for MDM2, respectively in  MDM 2 non-amplified compared with amplified cells. These findings correlated with larger increase in the levels of the proteins at 8 hours in the amplified cell lines, where 11(±2) vs 2(±2) fold increases were observed for MDM2 and 5(±1) fold vs 2(±1) fold for p53, respectively. In conclusion the rate of MDM2 and p53 turnover in  MDM 2 amplified cell lines is significantly greater than in non-amplified  MDM 2 cell lines. This is consistent with the rapid p53 activation, greater growth inhibitory and pro-apoptotic effect of MDM2-p53 binding antagonists in  MDM 2 amplified cells.
Adoptive Immunotherapy of p53-Mutated B-CLL with a Trifunctional Antibody (Anti-CD3 x Anti-CD20) and Allogeneic Donor Lymphocyte Transfusion.
Authors: Raymund Buhmann, Michael Stanglmaier, Belinda Simoes, Ting Yang, Peter Ruf, Horst Lindhofer, Hans-Jochem Kolb
Journal: Blood (2005)
GSTA1 *B1a Haplotype Associated with Lower Busulfan Clearance in Conditioning before HSCT in Pediatric Patients
Authors: Tiago Nava, Marc Ansari, Yves Theoret, Mohamed Aziz Rezgui, Samira Mezziani, Marie-France Vachon, Michel Duval, Henrique Bittencourt, Maja Krajinovic
Journal: Blood (2015)
Mitochondrial Ferritin Expression and Clonality of Hematopoiesis in Patients with Refractory Anemia with Ringed Sideroblasts.
Authors: Matteo G. Della Porta, Luca Malcovati, Anna Galli, Sabrina Boggi, Erica Travaglino, Carmela Marseglia, Margherita Maffioli, Sonia Levi, Paolo Arosio, Rosangela Invernizzi, Mario Lazzarino, Mario Cazzola
Journal: Blood (2005)
THU0326 Brain MRI in Patients with Acute Confusional State of Diffuse Psychiatric/neuropsychological Syndromes in Systemic Lupus Erythematosus
Authors: G. Abe, Y. Arinuma, Y. Sakuma, H. Kikuchi, S. Hirohata
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Neuropsychiatric systemic lupus erythematosus (NPSLE), especially diffuse psychiatric/neuropsychological syndromes (diffuse NPSLE), is one of the most difficult complications of the disease. For the evaluation and the diagnosis of central nervous system manifestations, including NPSLE, brain MRI is a very useful tool to detect the various abnormalities. We previously disclosed that patients with diffuse NPSLE and MRI abnormalities have more severe inflammation in the central nervous system compared with those without MRI abnormalities, as evidenced by poorer prognosis. Of note, acute confusional state (ACS) is the most recalcitrant manifestation in diffuse NPSLE. However, it remains unclear whether abnormalities in brain MRI still have any influences in patients with ACS. <h3>Objectives</h3> The aim of this study is to explore the differences in clinical characteristic between ACS patients with and without MRI abnormalities. <h3>Methods</h3> Thirty-six patients with ACS admitted to our University Hospitals from 1992 to 2015 were exhaustively enrolled in this study. Their medical charts and brain MRI scans were reviewed. The relationship of MRI abnormalities with various parameters was analyzed. <h3>Results</h3> As many as 19 of 36 patients (52.8%) had abnormal MRI findings. MRI findings improved after treatment in 14 of 19 patients for whom follow-up studies were available. Among the 5 patients without improvement of MRI findings, 4 patients died from active NPSLE itself. MRI abnormalities were not correlated with the age at the onset of ACS, the disease duration of SLE, the presence of anti-DNA antibody, anti-phospholipid antibodies, or anti-ribosomal P antibodies, and the levels of IL-6 in sera or cerebrospinal fluid. Notably, MRI abnormalities were significantly associated with the presence of serum anti-Sm antibodies (p=0.0005). Finally, the presence of MRI abnormalities in patients with ACS significantly increased the mortality (p=0.0013, HR=10.36 [95% CI: 2.487–43.19]) (figure). <h3>Conclusions</h3> These results demonstrate that patients with ACS of diffuse NPSLE with MRI abnormalities have more severe inflammation in the central nervous system, as evidenced by poorer prognosis. The data also indicate that anti-Sm in involved in the development of MRI abnormalities in ACS. <h3>Disclosure of Interest</h3> None declared
RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.
Authors: Steven Vesole, Xiaoying Jia, Aldo M. Roccaro, Antonio Sacco, Hai T. Ngo, Feda Azab, Abdel Kareem Azab, Molly R Melhem, Judith M. Runnels, Phong Quang, Kenneth C. Anderson, Irene M. Ghobrial
Journal: Blood (2009)
Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma
Authors: Ursula Rochau, Wolfgang Willenbacher, Ella Willenbacher, Beate Jahn, Vjollca Querimi, Christina Kurzthaler, Martina Kluibenschaedl, Annette Conrads-Frank, Guenther A. Gastl, Uwe Siebert
Journal: Blood (2013)
Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.
Authors: Bonnie K Arendt, Xiaosheng Wu, Philip R Greipp, S. Vincent Rajkumar, Robert Kyle, Rhett P Ketterling, Ryan A Knudson, Diane F Jelinek
Journal: Blood (2008)
AB0541 The Prognostic Significance of The Birmingham Vasculitis Activity Score (BVAS) in Patients with Systemic Vasculitis Transferred To The Intensive Care Unit (ICU)
Authors: F. Biscetti, A. Carbonella, F. Parisi, F. Cianci, S.L. Bosello, B. Tolusso, E. Gremese, G. Ferraccioli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic vasculitides represent a heterogeneous group of diseases that share clinical features including respiratory distress, renal dysfunction, and neurologic disorders. These diseases may often cause life-threatening complications requiring admission to an intensive care unit (ICU) [1]. Birmingham Vasculitis Activity Score (BVAS) is the most widely used generic tool to quantify disease activity in systemic vasculitis. Acute Physiology And Chronic Health Evaluation (APACHE II) is a simple and accurate assessment scale of the severity of disease in critically ill patients newly admitted to ICU. <h3>Objectives</h3> The aim of this study was to identify possible prognostic biomarkers for patients with vasculitis admitted to ICU. <h3>Methods</h3> A retrospective study was carried out from 2004 to 2014 in patients with systemic vasculitis admitted to the Rheumatology division and transferred to ICU due to clinical worsening, with a length of stay beyond 24 hours. An additional group of patients admitted to ICU, and without history of systemic vasculitis, were used as a matched-control group. A total of 25 patients were included in the analysis. <h3>Results</h3> ICU mortality was significantly associated with higher BVAS scores performed in the ward (p&lt;0.01) and at the admission in ICU (p=0.01), regardless of the value of APACHE II scores (p=0.50). We used receiver-operator characteristic (ROC) curve analysis to evaluate the possible cutoff value for the BVAS in the ward and in ICU and we found that a BVAS &gt;8 in the ward and that a BVAS &gt;10 in ICU were significantly related to the mortality in ICU (p&lt;0.01). <h3>Conclusions</h3> BVAS appears to be an excellent tool for assessing ICU mortality risk of patients with systemic vasculitides admitted to specialty departments. Our experience has shown that performing the assessment at admission to the ward is more important than determining the evaluation before the clinical aggravation causing the transfer to ICU. <h3>References</h3> Befort P, et al. BMC Anesthesiol. 2013 Oct 1;13(1):27 <h3>Disclosure of Interest</h3> None declared
Tet2 Uniquely Regulates Self-Renewal and Long Term Repopulating Capacity of Fetal Liver and Bone Marrow Hematopoietic Stem Cells
Authors: Hiroyoshi Kunimoto, Yumi Fukuchi, Masatoshi Sakurai, Daichi Abe, Ken Sadahira, Yasuo Ikeda, Shinichiro Okamoto, Hideaki Nakajima
Journal: Blood (2012)
Opioid Prescriptions for Chronic Pain and Overdose
Authors: Kate M. Dunn, Kathleen W. Saunders, Carolyn M. Rutter, Caleb J. Banta-Green, Joseph O. Merrill, Mark D. Sullivan, Constance M. Weisner, Michael J. Silverberg, Cynthia I. Campbell, Bruce M. Psaty, Michael Von Korff
Journal: Annals of Internal Medicine (2010)

As long-term opioid therapy for chronic noncancer pain is becoming more common in community practice, rates of fatal opioid overdose have increased. Dunn and coworkers found that 51 of 9940 adults ...
Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
Authors: Jorge Monge, K. Martin Kortüm, A. Keith Stewart, P. Leif Bergsagel, Joseph Mikhael, Craig B. Reeder, Angela Mayo, Rafael Fonseca
Journal: Journal of Clinical Oncology (2014)

8586 Background: Patients with multiple myeloma have experienced an increase in survival due to rescue options provided by novel agents used alone and in combination. There is a paucity of data for combinatorial regimens in this population. CYBORD has been validated as an upfront strategy with excellent long-term outcomes, but its use in relapsed disease has not been fully reported. We report a series of 55 pts with relapsed/refractory MM and their response to CYBORD. Methods: 55 pts with relapsed/refractory MM were treated with CYBORD on a 28 day cycle. Dosing was cyclophosphamide 300 mg/m2 PO q.wk; bortezomib 1 (2%), 1.3 (22%) or 1.5 mg/m2 (76%), IV (89%) or SQ (11%), once (87%) or twice weekly (13%); and dexamethasone 40 mg PO q.wk. We report response using the IMWG criteria, and new onset neuropathy based on NCI CTCAE. Results: Mean age was 65.6 years and 56% were male. Of the 55 pts, 64% had progressed while on therapy and 56% had a previous ASCT. Mean number of previous treatment lines was 3.3, and 36% and 82% were proteasome inhibitor (PI) and CYBORD naïve. Median follow up time was 24.1 mos and mean number of cycles was 5 (±4.4). ORR was 71%, 26% had ≥VGPR, and 13% CR. PI naïve pts had an ORR of 95% while pts who had previously received a PI had an ORR of 57%. Median PFS and OS were 9.2 and 29 mos. After a mean of 6 cycles, 22% of pts underwent subsequent ASCT. New onset grade 1 neuropathy was present in 16% of pts, while only 2% had grade 2 and none had grade 3 neuropathy. We found an increase in PFS in PI naïve pts (14.8 v 5.2 mos, HR 0.4, 95%CI 0.2-0.7), pts that underwent subsequent ASCT (19.7 v 6.3 mos, HR 0.3, 95%CI 0.2-0.7) and pts that had ≤3 prior treatment lines (12.1 v 6.1 mos, HR 0.5, 95%CI 0.2-0.8); no difference was found by mSMART risk or prior ASCT. An increase in OS was found only in PI naïve pts (35.4 v 21.2 mos, HR 0.5, 95%CI: 0.3-0.98) and pts that underwent subsequent ASCT (53.1 v 26.7 mos, HR 0.3, 95%CI 0.2-0.8); no difference was found by number of previous treatment lines, mSMART risk or prior ASCT. Conclusions: CYBORD is an effective treatment regimen without significant increase in side effect profile for pts with relapsed/refractory MM, achieving better outcomes in PI naïve pts and those who undergo subsequent ASCT, regardless of mSMART risk.
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
Authors: S. Faivre, P. Niccoli, D. Castellano, J.W. Valle, P. Hammel, J.-L. Raoul, A. Vinik, E. Van Cutsem, Y.-J. Bang, S.-H. Lee, I. Borbath, C. Lombard-Bohas, P. Metrakos, D. Smith, J.-S. Chen, P. Ruszniewski, J.-F. Seitz, S. Patyna, D.R. Lu, K.J. Ishak, E. Raymond
Journal: Annals of Oncology (2016)